+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028

  • ID: 5008475
  • Report
  • February 2020
  • Region: Asia Pacific
  • 44 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028

Summary

GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

The publisher epidemiologists utilized historical HSCT data available through country-wide registry reports in the 5GM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, The publisher epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, The publisher epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 5GM had 8,794 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 13,673 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 5.55%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 5GM. In the 5GM, the diagnosed incident cases of aGvHD will increase from 4,650 cases in 2018 to 7,212 cases in 2028, at an Annual Growth Rate (AGR) of 5.51% per year, and the diagnosed incident cases of cGvHD will increase from 4,144 cases in 2018 to 6,461 cases in 2028, at an AGR of 5.59% per year.

Scope
  • Graft Versus Host Disease (GvHD) Asia Pacific Epidemiology Report provides an overview of the risk factors and global trends of GvHD in the five growth markets (5GM: Australia, China, India, Japan, and South Korea).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 5GM: diagnosed incident cases of first allogeneic Hematopoietic stem cell transplantation (HSCT), acute GvHD (aGvHD), and chronic GvHD (cGvHD); diagnosed three-year prevalent cases of aGvHD and cGvHD; and diagnosed incident cases of aGvHD and cGvHD by grade and severity respectively. Additionally, 100-day mortality in aGvHD and one-year mortality cases in cGvHD is also included in this report.
  • The GvHD Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
Reasons to Buy

The GvHD Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global GvHD market.
  • Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the aGvHD grades and cGvHD severity stages that present the best opportunities for GvHD therapeutics in each of the markets covered.
  • Understand magnitude GvHD market by mortality rates and three-year prevalent cases.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Graft-Versus-Host Disease: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Australia
3.3.2 China
3.3.3 India
3.3.4 Japan
3.3.5 South Korea
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for GvHD (2018-2028)
3.5.1 Incident Cases of First Allogeneic HSCT
3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT
3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT
3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD
3.5.5 Diagnosed Incident Cases of aGvHD by Grade
3.5.6 Diagnosed Incident Cases of cGvHD by Severity
3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD
3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD
3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD
3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the publisher
4.4 Contact Information
4.5 Disclaimer

List of Tables

Table 1: Risk Factors for GvHD

List of Figures

Figure 1: 5GM, Diagnosed Incident Cases of GvHD in Diagnosed Incident Cases of First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018 and 2028
Figure 2: 5GM, Diagnosed Incidence of aGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 3: 5GM, Diagnosed Incidence of cGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 4: Case Flow Map of aGvHD and cGvHD
Figure 5: Sources Used for First Allogeneic HSCT
Figure 6: Sources Used for aGvHD and cGvHD in First Allogeneic HSCT
Figure 7: Sources Used for aGvHD Grades
Figure 8: Sources Used for cGvHD Severity
Figure 9: Sources Used for 100-Day Mortality of aGvHD and One-Year Mortality of cGvHD
Figure 10: Sources Used for Three-Year Diagnosed Prevalent Cases of aGvHD and cGvHD
Figure 11: 5GM, Diagnosed Incident Cases of First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 12: 5GM, Diagnosed Incident Cases of aGvHD in First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 13: 5GM, Diagnosed Incident Cases of cGvHD in First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 14: 5GM, Age-Specific Diagnosed Incident Cases of aGvHD and cGvHD in First Allogeneic HSCT Cases, Both Sexes, 2018
Figure 15: 5GM, Diagnosed Incident Cases of aGvHD by Grade, Both Sexes, All Ages, 2018
Figure 16: 5GM, Diagnosed Incident Cases of cGvHD by Severity, Both Sexes, All Ages, 2018
Figure 17: 5GM, 100-Day Mortality in Diagnosed Incident Cases of aGvHD, Both Sexes, All Ages, 2018 and 2028
Figure 18: 5GM, One-Year Mortality in Diagnosed Incident Cases of cGvHD, Both Sexes, All Ages, 2018
Figure 19: 5GM, Three-Year Diagnosed Prevalent Cases of aGvHD, Both Sexes, All Ages, 2018
Figure 20: 5GM, Three-Year Diagnosed Prevalent Cases of cGvHD, Both Sexes, All Ages, 2018
Note: Product cover images may vary from those shown
Adroll
adroll